Neuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity Research

Neuralstem (NASDAQ:CUR) had its target price reduced by research analysts at S&P Equity Research from $2.26 to $1.91 in a note issued to investors on Thursday. S&P Equity Research’s target price suggests a potential downside of 5.45% from the stock’s previous close.

Shares of Neuralstem (NASDAQ:CUR) traded down $0.06 on Thursday, hitting $2.02. The company’s stock had a trading volume of 278,300 shares, compared to its average volume of 570,156. The firm has a market capitalization of $30.59, a PE ratio of -1.22 and a beta of 1.60. Neuralstem has a 12 month low of $0.88 and a 12 month high of $6.60.

Neuralstem (NASDAQ:CUR) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) EPS for the quarter. Neuralstem had a negative return on equity of 148.94% and a negative net margin of 154,347.81%.

A hedge fund recently raised its stake in Neuralstem stock. National Asset Management Inc. increased its holdings in Neuralstem, Inc. (NASDAQ:CUR) by 9.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,985 shares of the company’s stock after acquiring an additional 1,937 shares during the quarter. National Asset Management Inc. owned approximately 0.19% of Neuralstem worth $134,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 7.05% of the company’s stock.

WARNING: This report was first reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/markets/neuralstem-cur-price-target-cut-to-1-91-by-analysts-at-sp-equity-research/1838138.html.

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.